Tag Archives: Warren Woessner

CLS Bank v. Alice Corp. (Part 2)

Posted on May 14, 2013 by Warren Woessner

I hope that some of my loyal readers noticed that my last post on CLS was incomplete, since it did not elaborate on the rationale for the decision(s) arrived at by the majority, either directly or by default. The first … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment

En (many) banc(s) Fed. Cir. decides CLS Bank v. Alice Corp. (Part 1)

Posted on May 13, 2013 by Warren Woessner

On May 10th, the Federal Circuit issued a short per curium opinion affirming the district court’s decision that “a majority of the court affirms the [holding below] that the asserted method and computer-readable media claims are not directed to eligible … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment

Allergan V. Sandoz – When Everything “Old” Is “New” Again

Posted on May 2, 2013 by Warren Woessner

On Tuesday, a divided panel of the Fed. Cir. found that Allergan’s claimed method of reducing the number of daily topical doses of brimonidine to treat glaucoma from 3 to 2 doses by administering a composition containing 0.2% brimonidine and … Continue reading →

Posted in Inherency | Tagged , , , , , , , , | Leave a comment

Marks & Clerk Releases Life Sciences 2013 Report

Posted on April 22, 2013 by Warren Woessner

On Monday, the international law firm Marks & Clerk released it’s 2013 Life Sciences Report at the BIO International Convention in Chicago. This 50-plus page report is wide-ranging, containing both the views of life science leaders on marketplace issues like … Continue reading →

Posted in Miscellaneous | Tagged , , , , , , , | Leave a comment